202 related articles for article (PubMed ID: 32406009)
21. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
[TBL] [Abstract][Full Text] [Related]
22. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
23. Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
Elyasi S; Shojaee FSR; Allahyari A; Karimi G
Phytother Res; 2017 Sep; 31(9):1323-1329. PubMed ID: 28635153
[TBL] [Abstract][Full Text] [Related]
24. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.
King TL; Voon PJ; Yuen KH; Mohamed Noor DA
Support Care Cancer; 2024 May; 32(6):345. PubMed ID: 38743316
[TBL] [Abstract][Full Text] [Related]
25. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Zhang RX; Wu XJ; Wan DS; Lu ZH; Kong LH; Pan ZZ; Chen G
Ann Oncol; 2012 May; 23(5):1348-1353. PubMed ID: 21940785
[TBL] [Abstract][Full Text] [Related]
26. Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.
Ostwal V; Kapoor A; Mandavkar S; Chavan N; Gupta T; Mirani J; Saklani A; Desouza A; Murugan K; Nashikkar C; Gupta S; Ramaswamy A
Oncologist; 2020 Dec; 25(12):e1886-e1892. PubMed ID: 32717127
[TBL] [Abstract][Full Text] [Related]
27. A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Corrie PG; Bulusu R; Wilson CB; Armstrong G; Bond S; Hardy R; Lao-Sirieix S; Parashar D; Ahmad A; Daniel F; Hill M; Wilson G; Blesing C; Moody AM; McAdam K; Osborne M
Br J Cancer; 2012 Aug; 107(4):585-7. PubMed ID: 22814578
[TBL] [Abstract][Full Text] [Related]
28. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
Schmulenson E; Krolop L; Simons S; Ringsdorf S; Ko YD; Jaehde U
Cancer Chemother Pharmacol; 2020 Sep; 86(3):435-444. PubMed ID: 32852627
[TBL] [Abstract][Full Text] [Related]
30. Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study.
Xiaozhe L; Meilan C; Beihui H; Junru L; Jingli G; Lifen K; Juan L
Integr Cancer Ther; 2022; 21():15347354221140402. PubMed ID: 36510385
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysis.
Zhou Y; Peng L; Li Y; Chen L
Biomed Rep; 2013 Nov; 1(6):873-878. PubMed ID: 24649045
[TBL] [Abstract][Full Text] [Related]
32. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
[TBL] [Abstract][Full Text] [Related]
33. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
[TBL] [Abstract][Full Text] [Related]
35. Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical.
Elyasi S; Rasta S; Taghizadeh-Kermani A; Hosseini S
Daru; 2022 Jun; 30(1):117-125. PubMed ID: 35320555
[TBL] [Abstract][Full Text] [Related]
36. Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial.
Xie Y; Wang Q; Hu T; Chen R; Wang J; Chang H; Peng X; Cheng J
Clin Breast Cancer; 2022 Jul; 22(5):e685-e690. PubMed ID: 35354530
[TBL] [Abstract][Full Text] [Related]
37. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Luo HY; Li YH; Wang W; Wang ZQ; Yuan X; Ma D; Wang FH; Zhang DS; Lin DR; Lin YC; Jia J; Hu XH; Peng JW; Xu RH
Ann Oncol; 2016 Jun; 27(6):1074-1081. PubMed ID: 26940686
[TBL] [Abstract][Full Text] [Related]
38. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.
Chen M; Zhang L; Wang Q; Shen J
PLoS One; 2013; 8(8):e72245. PubMed ID: 23977264
[TBL] [Abstract][Full Text] [Related]
39. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
Zielinski C; Lang I; Beslija S; Kahan Z; Inbar MJ; Stemmer SM; Anghel R; Vrbanec D; Messinger D; Brodowicz T
Br J Cancer; 2016 Jan; 114(2):163-70. PubMed ID: 26657657
[TBL] [Abstract][Full Text] [Related]
40. Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study.
Stein A; Quidde J; Schröder JK; Göhler T; Tschechne B; Valdix AR; Höffkes HG; Schirrmacher-Memmel S; Wohlfarth T; Hinke A; Engelen A; Arnold D
BMC Cancer; 2016 Feb; 16():82. PubMed ID: 26865161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]